Arteriosclerosis obliterans Peripheral arterial disease
Conditions
Interventions
None listed
Sponsors
Tanabe Pharma Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet both of the following criteria (1) and (2): (1)Diagnosed with ASO and scheduled to receive long-term oral antiplatelet therapy. (2)Not receiving sarpogrelate at the time of registration and meeting either of the following conditions: - Scheduled to receive one of the antiplatelet agents under study. - Scheduled to change to sarpogrelate or one of the other oral antiplatelet agents under study or receive it in addition to antiplatelet therapy.
Exclusion criteria
Exclusion criteria: The following subjects were excluded: (1)Those with contraindications to the use of targeted medication (sarpogrelate or antiplatelet agents). (2)Those considered inappropriate for the study by patient's physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Combined endpoint comprised of the following cardiovascular events; - Cerebrovascular events - Cardiovascular events - Peripheral vascular events | — |
Secondary
| Measure | Time frame |
|---|---|
| Cerebrovascular events Cardiovascular events Peripheral vascular events Total cardiovascular death Fatal cerebrovascular events Fatal cardiovascular events Fatal peripheral vascular events All causes of death Amputation Development of critical limb ischemia | — |
Countries
Japan
Contacts
Public ContactKaoru Ishizaki
Tanabe Pharma Corporation Pharmacovigilance Department
Outcome results
None listed